WEBULL
WebtradeDownload

Is Axsome Therapeutics (AXSM) A Bargain After Setting Its November 2 Earnings Date?

Simply Wall St · 1d ago

Axsome Therapeutics (AXSM) has set November 2, 2026, as the date for its third quarter earnings release, scheduled for before the U.S. market opens, along with a management call to discuss financial results and provide a business update.

Recent trading has been choppy for Axsome Therapeutics, with the share price down 18.16% over the past 30 days and 27.25% over 90 days. However, the 1-year total shareholder return of 38.82% and 5-year total shareholder return of 318.71% point to longer term momentum still in place.

Scan beyond Axsome Therapeutics and line up other potential breakout ideas with our handpicked 20 high quality undiscovered gems that share strong fundamentals but still fly under most investors' radar.

Recent volatility now collides with Axsome Therapeutics’ growing CNS portfolio, as well as its reported revenue and net income trends. Are you seeing a reset in sentiment, or a repricing of the underlying business as valuation comes into focus next?

Most Popular Narrative: 40% Undervalued

Compared with Axsome Therapeutics’ last close at $170.08, the most followed narrative points to a fair value of $282.51. This figure reflects an aggressive outlook for the CNS portfolio and a relatively low discount rate of 7.11%.

The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

See why 41 investors see Axsome Therapeutics as 40% undervalued.

Result: Fair Value of $282.51 (UNDERVALUED)

Still, Axsome Therapeutics faces real pressure if Auvelity or Sunosi underperform expectations, or if ongoing net losses and spending strain the current cash position.

Find out about the key risks to this Axsome Therapeutics narrative.

Next Steps

Mixed signals or a clear setup, either way Axsome Therapeutics deserves a closer look right now so you are not relying on headlines alone. To see what optimism in the data looks like in practice, review the 3 key rewards.

Looking for more Axsome Therapeutics style ideas?

If you only stop at Axsome Therapeutics, you could miss other opportunities that fit your approach, so widen your search now using focused stock lists.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.